DoP assures faster clearance for dengue vaccine

Image
Press Trust of India New Delhi
Last Updated : Sep 23 2015 | 6:48 PM IST
The Department of Pharmaceuticals will give all clearances on an urgent basis to dengue vaccine developed by any firm, Minister of State for Chemicals and Fertilisers Hansraj Gangaram Ahir said today.
At present, there is no dengue vaccine in India.
Yesterday, it was reported that Serum Institute of India was planning to seek approval to launch a drug to treat dengue virus.
According to reports, Serum has obtained rights from US-based Biotech Visterra to sell its dengue vaccine Monoclonal Antibody, VIS513.
"...Our government is sensible towards dengue virus, we are keeping a close watch on the prices of other medicines required for the treatment of the disease," Ahir said here while launching the revamped website of Department of Pharmaceuticals (DoP).
"If any company approaches our department for whatever clearances or any other approvals required for any dengue medicine, we will try to give it approval as early as possible, once cleared by the Health Ministry," Ahir told PTI.
Meanwhile, Delhi is in the grip of its worst Dengue outbreak in five years. Till Monday 25 deaths were reported and 4,000 people affected from the disease.
Dengue spreads through infected Aedes or the tiger mosquitoes biting people. Most patients recover and on a minuscule number die from dengue.
Meanwhile, the Union Health Ministry has issued an advisory to Delhi government to "intensify" measures to check the breeding of mosquitoes.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 23 2015 | 6:48 PM IST

Next Story